The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment
- PMID: 24851087
- PMCID: PMC4023453
- DOI: 10.2174/1570159X12666140324183406
The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment
Abstract
Schizophrenia is one of the most debilitating psychiatric diseases with a lifetime prevalence of approximately 1%. Although the specific molecular underpinnings of schizophrenia are still unknown, evidence has long linked its pathophysiology to postsynaptic abnormalities. The postsynaptic density (PSD) is among the molecular structures suggested to be potentially involved in schizophrenia. More specifically, the PSD is an electron-dense thickening of glutamatergic synapses, including ionotropic and metabotropic glutamate receptors, cytoskeletal and scaffolding proteins, and adhesion and signaling molecules. Being implicated in the postsynaptic signaling of multiple neurotransmitter systems, mostly dopamine and glutamate, the PSD constitutes an ideal candidate for studying dopamine-glutamate disturbances in schizophrenia. Recent evidence suggests that some PSD proteins, such as PSD-95, Shank, and Homer are implicated in severe behavioral disorders, including schizophrenia. These findings, further corroborated by genetic and animal studies of schizophrenia, offer new insights for the development of pharmacological strategies able to overcome the limitations in terms of efficacy and side effects of current schizophrenia treatment. Indeed, PSD proteins are now being considered as potential molecular targets against this devastating illness. The current paper reviews the most recent hypotheses on the molecular mechanisms underlying schizophrenia pathophysiology. First, we review glutamatergic dysfunctions in schizophrenia and we provide an update on postsynaptic molecules involvement in schizophrenia pathophysiology by addressing both human and animal studies. Finally, the possibility that PSD proteins may represent potential targets for new molecular interventions in psychosis will be discussed.
Keywords: Dopamine; NMDA; PSD-95; homer; kalirin; psychosis; shank; synaptic plasticity..
Figures

Similar articles
-
Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches.Mol Neurobiol. 2014 Feb;49(1):484-511. doi: 10.1007/s12035-013-8534-3. Epub 2013 Sep 3. Mol Neurobiol. 2014. PMID: 23999870 Review.
-
Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis.Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 1;46:1-12. doi: 10.1016/j.pnpbp.2013.06.010. Epub 2013 Jun 23. Prog Neuropsychopharmacol Biol Psychiatry. 2013. PMID: 23800465
-
Calcium-dependent networks in dopamine-glutamate interaction: the role of postsynaptic scaffolding proteins.Mol Neurobiol. 2012 Oct;46(2):275-96. doi: 10.1007/s12035-012-8293-6. Epub 2012 Jul 5. Mol Neurobiol. 2012. PMID: 22763587 Review.
-
Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia.Prog Neuropsychopharmacol Biol Psychiatry. 2014 Oct 3;54:299-314. doi: 10.1016/j.pnpbp.2014.07.003. Epub 2014 Jul 12. Prog Neuropsychopharmacol Biol Psychiatry. 2014. PMID: 25025505
-
Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins.Psychopharmacology (Berl). 2013 Jan;225(1):1-19. doi: 10.1007/s00213-012-2921-8. Epub 2012 Nov 21. Psychopharmacology (Berl). 2013. PMID: 23179966 Review.
Cited by
-
The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia.Biomolecules. 2023 Aug 5;13(8):1220. doi: 10.3390/biom13081220. Biomolecules. 2023. PMID: 37627285 Free PMC article. Review.
-
Disturbance of Metabotropic Glutamate Receptor-Mediated Long-Term Depression (mGlu-LTD) of Excitatory Synaptic Transmission in the Rat Hippocampus After Prenatal Immune Challenge.Neurochem Res. 2019 Mar;44(3):609-616. doi: 10.1007/s11064-018-2476-0. Epub 2018 Jan 20. Neurochem Res. 2019. PMID: 29353373
-
Unraveling multi-scale neuroimaging biomarkers and molecular foundations for schizophrenia: A combined multivariate pattern analysis and transcriptome-neuroimaging association study.CNS Neurosci Ther. 2024 Aug;30(8):e14906. doi: 10.1111/cns.14906. CNS Neurosci Ther. 2024. PMID: 39118226 Free PMC article.
-
Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice.Mol Brain. 2015 Aug 12;8:47. doi: 10.1186/s13041-015-0139-5. Mol Brain. 2015. PMID: 26260027 Free PMC article.
-
Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia.Front Psychiatry. 2020 May 14;11:369. doi: 10.3389/fpsyt.2020.00369. eCollection 2020. Front Psychiatry. 2020. PMID: 32477178 Free PMC article. Review.
References
-
- Leucht S, Corves C, Arbter D, Engel R R, Li C, Davis J M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373 (9657):31–41. - PubMed
-
- Schwartz T L, Sachdeva S, Stahl S M. Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia. Curr. Pharm. Des. 2012;18 (12):1580–92. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources